Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Rage Against the Machine -- Ignore unavailable to you. Want to Upgrade?

To: James Calladine who wrote (371)	6/10/2002 9:49:58 AM
From: James Calladine	Respond to of 1296

JUST "good manners" TO SHARE WITH YOUR FRIENDS, RIGHT? ImClone Had Early Word on FDA Rejection of Erbitux WASHINGTON -- ImClone Systems (NasdaqNM: IMCL - News) Inc. (IMCL) officials learned the Food and Drug Administration might turn away the company's application for its promising and financially vital cancer drug Erbitux three days before the agency on Dec. 28 formally told the company the news, people close to the situation told The Wall Street Journal. Between the time Harlan Waksal, then chief operating officer, learned of the possible FDA action and the time the agency actually notified the company of its action, several Waksal family members and a close friend of the former chief executive, Samuel Waksal, sold ImClone stock, these people say. That close friend, celebrity entrepreneur Martha Stewart, left a message for Samuel Waksal the day she sold her shares, although Ms. Stewart's representatives say the call came after she ordered the trade be made....